Therapeutic Potential of Mesenchymal Stem Cells for Severe Acute Lung Injury
Therapeutic Potential of Mesenchymal Stem Cells for Severe Acute Lung Injury
复制标题
DOI：
10.1378/chest.10-0518
复制
发表时间：
2010-10-01
期刊：
影响因子：
9.6
通讯作者：
Lee, Jae Woo
中科院分区：
文献类型：
--
作者：
Matthay, Michael A.;Thompson, B. Taylor;Lee, Jae Woo
临床前研究表明，同种异体人间充质干细胞（MSC）可用于治疗几种临床疾病，包括败血症，急性肾衰竭，急性心肌梗死，以及最近的急性肺损伤（ALI）。本文简要综述了MSC的生物学特性，使其适用于治疗人类疾病，以及实验数据，为急性肺损伤急性呼吸衰竭危重患者的潜在疗效提供支持。然后，文章讨论了哪些ALI患者可能是基于细胞的治疗的最佳候选人，并为在严重ALI患者中测试同种异体人MSC所需的监管和实际步骤提供了模板。如何设计试验来测试安全性和有效性是一个双重焦点。胸部2010;138（4）：965-972
Preclinical studies indicate that allogeneic human mesenchymal stein cells (MSC) may be useful for the treatment of several clinical disorders, including sepsis, acute renal failure, acute myocardial infarction, and more recently, acute lung injury (ALI). This article provides a brief review of the biologic qualities of MSC that make them suitable for the treatment of human diseases, as well as the experimental data that provide support for their potential efficacy for critically ill patients with acute respiratory failure from ALI. The article then discusses which patients with ALI might be the best candidates for cell-based therapy and provides a template for the regulatory and practical steps that will be required to test allogeneic human MSC in patients with severe ALI. There is a dual focus on how to design trials for testing both safety and efficacy. CHEST 2010;138(4):965-972